Wet granulation is mostly used process for manufacturing matrix tablets. Compared to the direct compression method, it allows for a better flow and compressibility properties of compression mixtures. Granulation, including process parameters and tableting, can influence critical quality attributes (CQAs) of hydrophilic matrix tablets. One of the most important CQAs is the drug release profile. We studied the influence of granulation process parameters (type of nozzle and water quantity used as granulation liquid) and tablet hardness on the drug release profile. Matrix tablets contained HPMC K4M hydrophilic matrix former and carvedilol as a model drug. The influence of selected HPMC characteristics on the drug release profile was also evaluated using two additional HPMC batches. For statistical evaluation, partial least square (PLS) models were generated for each time point of the drug release profile using the same number of latent factors. In this way, it was possible to evaluate how the importance of factors influencing drug dissolution changes in dependence on time throughout the drug release profile. The results of statistical evaluation show that the granulation process parameters (granulation liquid quantity and type of nozzle) and tablet hardness significantly influence the release profile. On the other hand, the influence of HPMC characteristics is negligible in comparison to the other factors studied. Using a higher granulation liquid quantity and the standard nozzle type results in larger granules with a higher density and lower porosity, which leads to a slower drug release profile. Lower tablet hardness also slows down the release profile.

Download full-text PDF

Source
http://dx.doi.org/10.1080/03639045.2018.1483394DOI Listing

Publication Analysis

Top Keywords

release profile
32
drug release
24
tablet hardness
16
granulation process
12
matrix tablets
12
process parameters
12
granulation liquid
12
drug
9
profile
9
granulation
8

Similar Publications

Resistant hypertension is defined as office blood pressure >140/90 mm Hg with a mean 24-hour ambulatory blood pressure of >130/80 mm Hg in patients who are compliant with 3 or more antihypertensive medications. Those who persistently fail pharmaceutical therapy may benefit from interventional treatment, such as renal denervation. Sympathetic nervous activity in the kidney is a known contributor to increased blood pressure because it results in efferent and afferent arteriole vasoconstriction, reduced renal blood flow, increased sodium and water reabsorption, and the release of renin.

View Article and Find Full Text PDF

Controlled-release microparticles offer a promising avenue for enhancing patient compliance and minimizing dosage frequency. In this study, we aimed to design controlled-release microparticles of Glipizide utilizing Eudragit S100 and Methocel K 100 M polymers as controlling agents. The microparticles were fabricated through a simple solvent evaporation method, employing various drug-to-polymer ratios to formulate different controlled-release batches labeled as F1 to F5.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Eli Lilly and Company, Indianapolis, IN, USA.

Background: Alzheimer's and Synuclein diseases are characterized by distinct biomarkers and frequently co-occur, suggesting potential interactions between their pathological pathways. This study leverages amyloid and tau PET imaging, along with CSF Phosphorylated tau (P-tau) and alpha-synuclein measurements from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to investigate the impact of co-pathology on cognitive functions.

Method: We conducted an analysis using ADNI data (Table 1) from the 2024-01-08 download, including results from the CSF alpha-Synuclein Seed Amplification Assay (SAA, 2023-09-29 release, 1637 samples out of 1638 records included in the analysis).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

University of Exeter, Exeter, Devon, UK.

Background: Establishing novel biomarkers to detect of Alzheimer's disease (AD) and Lewy body dementia (LBD) neuropathology is integral to support early diagnosis and the differentiation between dementia subtypes. Neural-derived extracellular vesicles (NDEVs) - released by neural cells into circulation - provide promise in this regard. NDEV cargo, such as p-T181-tau and Aβ-42, have previously been shown to be associated with cognitive decline and disease progression among AD patients (Winston et al, 2016; Kapogiannis et al, 2019).

View Article and Find Full Text PDF

Background: There is a critical need for minimally-invasive robust peripheral markers of neurodegenerative conditions. Peripheral RNA may be a powerful tool for in-depth tracking of biological processes in AD and related disorders. Here, we combine whole-blood microarray data from Alzheimer's Disease Neuroimaging Initiative (ADNI; N=743) and RNA-Seq from Translational Biomarkers in Aging and Dementia (TRIAD; N=77) and Montreal Neurological Institute (MNI; N=33) cohorts to predict cognitive performance across AD spectrum.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!